ARS Pharmaceuticals
ARS Pharmaceuticals is dedicated to developing patient-friendly, needle-free treatments for severe allergic reactions, including an investigational intranasal epinephrine spray called neffy. The company aims to provide a reliable, easy-to-use alternative to traditional epinephrine auto-injectors, with a focus on safety, convenience, and rapid administration. ARS is advancing its product through clinical development and regulatory review, with a mission to improve emergency treatment options for allergy sufferers.
Industries
Nr. of Employees
small (1-50)
Patents
Products
neffy (epinephrine nasal spray)
An intranasal epinephrine spray developed to provide rapid systemic absorption comparable to intramuscular epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis.
neffy (epinephrine nasal spray)
An intranasal epinephrine spray developed to provide rapid systemic absorption comparable to intramuscular epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis.
Expertise Areas
- Intranasal drug delivery development
- Pharmacokinetics and bioequivalence assessment
- Clinical trial design and registration programs
- Regulatory affairs (FDA and EMA submissions and designations)
Key Technologies
- Intranasal/mucosal drug delivery
- Nasal absorption-enhancing excipients
- Pharmacokinetic (PK) and pharmacodynamic (PD) assays
- Bioequivalence study design
News & Updates
A conference call to discuss the merger and the potential commercialization of neffy, ARS’s needle-free epinephrine nasal spray.
The U.S. Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray, covering fast-acting decreased dosage level for type 1 allergic reactions.
A patent covering a fast-acting decreased dosage level for intranasal administration for type 1 allergic reactions, issued by the USPTO on June 16, 2020.
A conference call to discuss the merger and the potential commercialization of neffy, ARS’s needle-free epinephrine nasal spray.
The U.S. Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray, covering fast-acting decreased dosage level for type 1 allergic reactions.
A patent covering a fast-acting decreased dosage level for intranasal administration for type 1 allergic reactions, issued by the USPTO on June 16, 2020.